Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study

Marina Cuchel(Translational Therapeutics (United States)), Emma A. Meagher(Translational Therapeutics (United States)), Hendrik du Toit Theron(Netcare Unitas Hospital), Dirk Blom(University of Cape Town), A. David Marais(South African Medical Research Council), Robert A. Hegele(Western University), Maurizio Averna(University of Palermo), Cesare R. Sirtori(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Prediman K. Shah(Cedars-Sinai Medical Center), Daniel Gaudet(Université du Québec à Chicoutimi), Claudia Stefanutti(Sapienza University of Rome), Giovanni Battista Vigna(University of Ferrara), Anna ME Du Plessis(University of Pretoria), Kathleen J. Propert(Translational Therapeutics (United States)), William J. Sasiela(Aegerion Pharmaceuticals (United States)), LeAnne T. Bloedon(Translational Therapeutics (United States)), Daniel J. Rader(University of Pennsylvania)
The Lancet
November 2, 2012
Cited by 737Open Access
Full Text

Abstract


Related Papers

No related papers found

Powered by citation graph analysis